CX-072 is a wholly owned PD-L1-targeting Probody therapeutic for the treatment of cancer, currently being evaluated in a Phase 1/2 clinical trial. To support initiation of the study, CytomX launched PROCLAIM (Probody Clinical Assessment In Man), a clinical trial program that enables clinical study sites and physicians to access our Probody therapeutics under one international umbrella.
The first module within the PROCLAIM program is an open-label, dose-finding Phase 1/2 study evaluating CX-072 as monotherapy and in combination with Yervoy® (ipilimumab) or Zelboraf® (vemurafenib) in patients with certain cancers.
Initial clinical data was presented at the ASCO, ESMO and SITC 2018 Annual Meetings as well as CytomX’s 2019 R&D Day. In preclinical studies, CX-072 demonstrated anti-tumor activity, while reducing activation of the immune system outside the tumor.
CytomX aims to achieve three goals as part of the PROCLAIM-CX-072 clinical trial: